Umut Kocabas, Isil Ergin, Veysel Yavuz, Cihan Altın, Mehmet Kaplan, Gülsüm Meral Yılmaz Öztekin, Mustafa Doğduş, Selda Murat, Bektaş Murat, Tarık Kıvrak, Dilay Karabulut, Ersin Kaya, İbrahim Halil Özdemir, Cennet Yıldız, Fatma Özge Salkın, Emre Özçalık, Şeyda Günay Polatkan, Fahri Çakan, Taner Şen, Umut Karabulut, Sinem Çakal, Ersan Oflar, Ümit Yaşar Sinan, Mustafa Yenerçağ, Uğur Önsel Türk
{"title":"心力衰竭患者使用 Empagliflozin 和 Dapagliflozin 的真实世界数据：RED-HEART研究。","authors":"Umut Kocabas, Isil Ergin, Veysel Yavuz, Cihan Altın, Mehmet Kaplan, Gülsüm Meral Yılmaz Öztekin, Mustafa Doğduş, Selda Murat, Bektaş Murat, Tarık Kıvrak, Dilay Karabulut, Ersin Kaya, İbrahim Halil Özdemir, Cennet Yıldız, Fatma Özge Salkın, Emre Özçalık, Şeyda Günay Polatkan, Fahri Çakan, Taner Şen, Umut Karabulut, Sinem Çakal, Ersan Oflar, Ümit Yaşar Sinan, Mustafa Yenerçağ, Uğur Önsel Türk","doi":"10.1002/ehf2.15049","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>We aimed to determine the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19–101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (<i>P</i> = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (<i>P</i> < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06–3.05; <i>P</i> = 0.027], higher household income (OR: 3.46; 95% CI: 1.27–9.42; <i>P</i> = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16–6.35; <i>P</i> = 0.021), diabetes (OR: 9.42; 95% CI: 6.72–13.20; <i>P</i> < 0.001), the use of angiotensin receptor–neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39–7.01; <i>P</i> < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49–2.75; <i>P</i> < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18–2.22; <i>P</i> = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30–2.29; <i>P</i> < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45–0.88; <i>P</i> = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37–0.76; <i>P</i> = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48–0.98; <i>P</i> = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49–0.91; <i>P</i> = 0.010) were independently associated with the non-use of SGLT2is.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The RED–HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.</p>\n </section>\n </div>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":"12 1","pages":"434-446"},"PeriodicalIF":3.2000,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769646/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study\",\"authors\":\"Umut Kocabas, Isil Ergin, Veysel Yavuz, Cihan Altın, Mehmet Kaplan, Gülsüm Meral Yılmaz Öztekin, Mustafa Doğduş, Selda Murat, Bektaş Murat, Tarık Kıvrak, Dilay Karabulut, Ersin Kaya, İbrahim Halil Özdemir, Cennet Yıldız, Fatma Özge Salkın, Emre Özçalık, Şeyda Günay Polatkan, Fahri Çakan, Taner Şen, Umut Karabulut, Sinem Çakal, Ersan Oflar, Ümit Yaşar Sinan, Mustafa Yenerçağ, Uğur Önsel Türk\",\"doi\":\"10.1002/ehf2.15049\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>We aimed to determine the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19–101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (<i>P</i> = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (<i>P</i> < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06–3.05; <i>P</i> = 0.027], higher household income (OR: 3.46; 95% CI: 1.27–9.42; <i>P</i> = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16–6.35; <i>P</i> = 0.021), diabetes (OR: 9.42; 95% CI: 6.72–13.20; <i>P</i> < 0.001), the use of angiotensin receptor–neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39–7.01; <i>P</i> < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49–2.75; <i>P</i> < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18–2.22; <i>P</i> = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30–2.29; <i>P</i> < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45–0.88; <i>P</i> = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37–0.76; <i>P</i> = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48–0.98; <i>P</i> = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49–0.91; <i>P</i> = 0.010) were independently associated with the non-use of SGLT2is.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The RED–HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11864,\"journal\":{\"name\":\"ESC Heart Failure\",\"volume\":\"12 1\",\"pages\":\"434-446\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11769646/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESC Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15049\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ehf2.15049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study
Aims
We aimed to determine the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.
Methods
Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.
Results
The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19–101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06–3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27–9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16–6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72–13.20; P < 0.001), the use of angiotensin receptor–neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39–7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49–2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18–2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30–2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45–0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37–0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48–0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49–0.91; P = 0.010) were independently associated with the non-use of SGLT2is.
Conclusions
The RED–HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.
期刊介绍：
ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
